May 03, 2024 / 12:15PM GMT
Peter Verdult - Citigroup Inc., Research Division - MD
Good afternoon, everyone. Welcome to the revamped Stirling Square Bank, and good afternoon to everyone in the room. And to those listening on the webcast, good morning, good afternoon, good evening. It's been a very busy week for earnings and in other events, but we are ending the week on a high with the Q1 ratio of Novo Nordisk.
The speakers don't really need introduction, but just out of courtesy, Karsten, Group's CFO; Camilla, Group Commercial Strategy Head; and last but not least, Martin, Head of R&D, joined by us and already of Investor Relations.
Now usually, I'd be saying without further ado, hand it straight over to Karsten to some slides and some Q&A. But I think it is worth just pausing and recognizing that it is Mr. Daniel Bohsen, his last function as the Head of Novo Investor Relations. And I think that needs to be sort of recognized by the audience in the room, not just yet, but when I say. But on that note, I have known Danny, I think, for over 15 years. He was in the (inaudible) analyst covering Novo Nordisk.
Q1 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript
May 04, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers